MacLaren R, Patrick W D, Hall R I, Rocker G M, Whelan G J, Lima J J
School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA.
Clin Ther. 2001 Nov;23(11):1855-66. doi: 10.1016/s0149-2918(00)89081-5.
Placebo-controlled studies have indicated that both cisapride and metoclopramide promote gastric motility in critically ill patients.
This study was conducted to compare cisapride and metoclopramide for facilitating gastric emptying and improving tolerance to intragastric enteral nutrition (EN) and to evaluate the relationship between aspirated gastric residual volume and gastric emptying function in this patient population.
In this double-blind study, critically ill, mechanically ventilated patients with an aspirated gastric residual volume > or = 150 mL while receiving intragastric EN were randomized to receive enteral cisapride 10 mg or metoclopramide 10 mg every 6 hours for a total of 7 doses. The acetaminophen-absorption method was used to assess gastric emptying at baseline and 30 minutes after the seventh dose by determining the area under the plasma concentration-time curve at 240 minutes (AUC240), maximum concentration (Cmax), and time to Cmax (Tmax). Gastric residual volume was measured every 6 hours before dosing.
Fourteen patients were included in the study, 7 in each group. Patient characteristics were similar in the 2 groups. Compared with baseline, metoclopramide significantly accelerated Tmax (39.00 +/- 15.56 min with metoclopramide vs 103.71 +/- 47.35 min at baseline; P = 0.018) and increased Cmax (12.94 +/- 6.68 mg/L vs 6.97 +/- 4.78 mg/L; P = 0.018) and AUC240 (1,421.43 +/- 780.31 mg/L x min vs 839.00 +/- 545.58 mg/L x min; P = 0.043). Cisapride increased Cmax from baseline (12.27 +/- 8.95 mg/L vs 4.53 +/- 2.37 mg/L, respectively), but the difference was not statistically significant. Gastric residual volume was significantly reduced from baseline after 3 doses of metoclopramide (from 268.7 +/- 112.3 mL to 57.0 +/- 23.1 mL; P < 0.05) and was significantly lower after the seventh dose of metoclopramide than after the seventh dose of cisapride (5.3 +/- 8.2 mL vs 41.4 +/- 39.7 mL, respectively; P = 0.05). Cmax at baseline and residual volume at study entry were inversely correlated (r = -0.50; P = 0.049).
Both cisapride and metoclopramide enhanced gastric motility and improved tolerance to intragastric EN. Metoclopramide reduced gastric residual volume to a significantly greater extent than did cisapride. Only Cmax at baseline was inversely associated with residual volume.
安慰剂对照研究表明,西沙必利和甲氧氯普胺均可促进危重症患者的胃动力。
本研究旨在比较西沙必利和甲氧氯普胺促进胃排空及改善对胃内肠内营养(EN)耐受性的效果,并评估该患者群体中胃内残留量与胃排空功能之间的关系。
在这项双盲研究中,接受胃内EN且胃内残留量≥150 mL的危重症机械通气患者被随机分为两组,分别每6小时接受10 mg肠内西沙必利或10 mg甲氧氯普胺治疗,共7剂。采用对乙酰氨基酚吸收法,通过测定240分钟时血浆浓度-时间曲线下面积(AUC240)、最大浓度(Cmax)和达峰时间(Tmax),在基线及第七剂给药后30分钟评估胃排空情况。给药前每6小时测量一次胃内残留量。
14例患者纳入研究,每组7例。两组患者特征相似。与基线相比,甲氧氯普胺显著加快了Tmax(甲氧氯普胺组为39.00±15.56分钟,基线时为103.71±47.35分钟;P = 0.018),增加了Cmax(分别为12.94±6.68 mg/L和6.97±4.78 mg/L;P = 0.018)及AUC240(分别为1421.43±780.31 mg/L·min和839.00±545.58 mg/L·min;P = 0.043)。西沙必利使Cmax较基线增加(分别为12.27±8.95 mg/L和4.53±2.37 mg/L),但差异无统计学意义。甲氧氯普胺3剂后胃内残留量较基线显著降低(从268.7±112.3 mL降至57.0±23.1 mL;P < 0.05),且第七剂甲氧氯普胺后胃内残留量显著低于第七剂西沙必利后(分别为5.3±8.